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Purpose. (e purposes of this study are to assess the acute effects of iodixanol, an iso-osmolar contrast media, on pulmonary
functions and to evaluate the body composition in order to find out its role in causing this deterioration.Methods. 35 male and 25
female patients undergoing diagnostic coronary angiography (CA) were enrolled in the study. Before CA, all patients’ body
compositions were evaluated by measuring their body mass indexes (BMIs) and waist-to-hip ratios (WHRs). Total body waters
(TBWs), fat masses (FMs), fat-free masses (FFMs), and basal metabolism rates (BMRs) were measured via bioimpedance analysis.
(e CAwas performed via radial artery route using iodixanol in every patient.(e pulmonary function tests of these patients were
performed before, during, and 2 hours after the CA. FEV1∆, FEF25–75%∆, and FVC∆ parameters were calculated by subtracting the
measured baseline value from the measurement after the CA. Results. Angiography caused significant reduction in forced
expiratory volume in 1 sec (FEV1, from 94.17± 18.83 to 84.45± 18.31, p< 0.0001), forced vital capacity (FVC, from 96.57± 15.82
to 88.31± 17.96, p< 0.0001), and forced expiratory flow at 25–75% (FEF25–75% from 82.54± 24.26 to 72.11± 25.41, p � 0.001) and
remained lower after 2 h after CA in male patients, respectively. FEV1 values were 103.40± 17.79 to 94.96± 17.063 (p � 0.004);
FVC values were 107.20± 19.03 to 99.08± 20.56 (p � 0.009); and FEF25–75% values were 83.92± 24.30 to 73.24± 20.45 (p � 0.005)
before and after CA and remained lower after 2 h after CA in female patients, respectively. FEV1/FVC ratio remained unchanged.
FEF25–75%∆ was statistically correlated with FFM, TBW, and WHR (p < 0.05; r � −0.344, r � −0.347, and r � 0.357, resp.), and
FVC∆ was correlated with WHR in male patients (p � 0.018, r � 397). Conclusions. Our data suggested that diagnostic CA using
iodixanol, an iso-osmolar contrast media, leads significant impairment in respiratory functions. Due to the persistence of these
reductions even 2 hours after CA, ventilatory functions should be considered especially in patients whose body compositions or
hydration levels are not within the desired physiological range.
1. Introduction
Coronary angiography still remains a gold standard di-
agnostic tool for the definite diagnosis of coronary artery
disease. Although the diagnostic accuracy and the tolerance
of the currently available contrast agents are high, their
administration may cause acute complications in patients
with increased risks. Moreover, interventional cardiology
patients, such as acute myocardial infarction patients,
may already be subject to a higher complication risk due to
the underlying conditions, and the contrast agent that is
used may even have cardiac adverse effects and complica-
tions [1]. Contrast media-related complications, as well as
the cardiovascular problems, are among the causes for
hospitalizing the patients and related financial burdens
[2, 3].
Given that the number of the types of the interventional
cardiology procedures has been increasing over the past few
years, the search for a better-tolerated agent continues to
eliminate the risks associated with contrast agents. Iso-
osmolar contrast agent is one of the nonionic iodinated
contrast agent types, in line with the evidence that it has
fewer side effects than low-osmolar contrast media [4].
Among those complications, contrast-induced nephrop-
athy is studied in the majority of published literature before.
Adverse effects of angiographic contrast agents diminished
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dramatically by clinical precautions, premedications before
the angiography, reducing the amount of contrast agent
usage, and also increasing the usage of iso-osmolar nonionic
angiographic contrast agents during angiography procedures.
Respiratory system, while it works together with the
cardiovascular system for oxygen homeostasis, can be di-
rectly affected by cardiovascular disorders [5] or indirectly
by diagnostic contrast agents. (ere are scarce data on the
adverse effects of angiographic contrast agents on re-
spiratory functions. Although vasovagal and chemotoxic-
organ-specific side effects [6] of contrast agent are evaluated,
there are a little data about the respiratory effects associated
to those contrast agents. We have thought that osmolality
does matter in respiratory functions during CA and an iso-
osmolar contrast agent might be safe. Furthermore, body
composition might have a role in respiratory functional
changes during CA using a contrast agent. We aimed at
evaluating the acute effects of iodixanol, an iso-osmolar
contrast agent, on pulmonary functions and at evaluating
the body composition regarding the question of whether it
plays a potential role in causing this deterioration.
2. Methods
2.1. Study Design. A study group was chosen among the
patients who had been planned diagnostic CA: sixty of 95
consecutive patients undergoing diagnostic coronary angi-
ography. 35 male and 25 female patients who fulfil the in-
clusion and exclusion criteria were enrolled in the study.
Before CA, all patients’ body compositions were evaluated by
measuring their body mass indexes (BMIs) and waist-to-hip
ratios (WHRs). Total body waters (TBWs), fat masses (FMs),
fat-free masses (FFMs), and basal metabolism rates (BMRs)
were measured via bioimpedance analysis. (e CA was
performed via radial artery route by the standard technique as
three projections for the left system coronary arteries and two
projections for the right coronary artery using iodixanol in
every patient.
Participants with clinically significant respiratory disease
(asthma, chronic obstructive or restrictive pulmonary dis-
ease), anormal pulmonary function test results before CA
(FVC%< 80%, FEV1< 80%, FEV1/FVC< 75%), cardiovas-
cular disease (myocardial infarction, previous coronary
intervention or surgery, and peripheral arterial disease),
renal insufficiency (estimated glomerular filtration rate
<60ml/min), and previous allergic reactions to contrast-
agent exposure were not enrolled in the study. Patients with
critical coronary lesions on coronary angiography were
excluded from the study. And also patients who requiring
left ventriculography, total contrast agent volume exceeding
60 cc, difficulty to engage coronary ostium by diagnostic
catheters or exchanging from radial route to femoral route,
and failure of radial artery cannulation during CA were
excluded the study.
Further exclusion criteria for the study were as follows:
moderate-to-severe valvular heart disease, history of pul-
monary embolism, pulmonary hypertension (mean pul-
monary artery pressure >40mmHg on echocardiography),
abnormal serum electrolyte values, and abnormal thyroid
function. A written consent was obtained from all the
patients, and our local ethical committee approved the
study.
2.2. Assessment and Measures. Body compositions were
evaluated using the bioelectrical impedance method (TBF-
300® device; Tanita, Illinois, USA). Body mass indexes
(BMIs), basal metabolism rates (BMRs), body fat masses
(BFMs), fat-free masses (FFMs), and total body waters
(TBWs) of the patients were measured. (e waist-to-hip
ratios (WHRs) were obtained by dividing the waist cir-
cumference to the hip circumference.
Pulmonary function tests (PFTs) were performed in
accordance with the American (oracic Society (ATS)
criteria, using a pulmonary function analyser (MIR Spirolab
III, Oberthulba, Germany). Individuals were informed be-
fore the measurements. First test was performed in a com-
fortable sitting position followed by a 15min of resting.
A mouthpiece was placed between the teeth and lips. (en,
a strong expiration was performed by the patient followed by
a deep inspiration after breathing 3 times in a relaxed way.
(e test was repeated 3 times to obtain the best values. FVC,
FEV1, FEV1/FVC, forced expiratory flow between 25% and
75% of FVC (FEF25–75%), FVC% (expected), FEV1% (ex-
pected), FEV1/FVC% (expected), and FEF25–75% (expected)
were also measured. (en, coronary angiography routine
procedures were performed through radial artery route by
a single experienced angiographer with catheter exchange
using 5 F Judkins diagnostic catheters over a 0.035-inch
guide wire. Totally, six multiple-angled views of the left and
right coronary arteries were recorded in all patients after
hand injection. (e contrast agent studied was iodixanol, an
iodine-containing nonionic radiocontrast agent with a mo-
lecular weight of 1550.20 and iodine content of 49.1. (e
concentration used for the study was a commercially
available formulation (Visipaque-320) containing osmolality
of 290mOsm/kg of water. All respiratory measurements
were repeated immediately after CA and 2 hours after CA.
FEV1∆, FEF25–75%∆, and FVC∆ parameters were calculated
by subtracting the measured baseline value from the mea-
surement after CA.
2.3. Statistical Analysis. Final data were evaluated by using
the statistical package programme (SPSS 15 Chicago Inc.).
Chi-square test or Fisher’s exact test was used to evaluate
categorical data. Whether continuous data had normal
distribution or not, Shapiro–Wilks normality test was used.
Independent t-test was used to compare differences between
groups for continuous data. Paired samples’ t-test was used
to determine the difference between pretest and posttest. All
the categorical data showed with frequencies and percent-
ages, and all continuous variables showed mean± standard
division (mean± SD) as descriptive statistics. Statistical
boundary was given as 0.05. SPSS software version 20.0 for
Windows (SPSS Inc., Chicago, IL, USA) was used for all
statistical analyses. All data were tested for normality, and
the appropriate nonparametric or parametric statistics were
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used. (e numeric variables were compared using Wilcoxon
rank-sum test. Any p value less than 0.05 was accepted as
significant.
3. Results
Twenty-five female (56.44± 8.85) and 35 male patients
(57.85± 11.91) were enrolled in the study. Characteristics of
the patients are summarized in Table 1.(emean of the used
contrast media was 40ml for each patient.
A significant fall in FEV1% (from 94.17± 18.83 to
84.45± 18.31, p< 0.0001), FVC% (from 96.57± 15.82 to
88.31± 17.96, p< 0.0001), and FEF25–75% (from 82.54±
24.26 to 72.11± 25.41, p � 0.001) were seen after CA and
insisted 2 h after CA inmale patients. FEV1% (from 103.40±
17.79 to 94.96± 17.063, p:0.004), FVC% (from 107.20±
19.03 to 99.08± 20.56, p � 0.009), and FEF25–75% (from
83.92± 24.30 to 73.24± 20.45, p � 0.005) were significantly
decreased and insisted 2 h after CA in female patients
(p< 0.01, p< 0.05, and p< 0.01, resp.; Table 2). FVC% values
of 12 male and 6 female patients and FEV1% values of 18
male and 3 female patients were below 80% after CA. FVC%
values of 10 male and 4 female patients and FEV1% values of
16 male and 2 female patients were below 80% 2 h after CA.
Only three male patients’ FEV1/FVC values were below 75%
(8.6% of men) after CA. However, FEV1/FVC ratio
remained unchanged after CA (p � 0.237) and 2 h after CA
(p � 0.341) in patients.
In female patients, body mass index was 34.12± 6.91,
BMR was 6172.40± 823.53, BFM% was 40.68± 5.15, BFMkg
was 34.10± 11.52, FFM was 47.56± 6.74, TBW was 34.93±
4.99, and WHR was 0.85± 0.05. In male patients, body mass
index was 28.72± 6.12, BMR was 7126.06± 1035.63, BFM%
was 24.88± 8.23, BFMkg was 21.80± 10.74, FFM was 61.08±
9.06, TBW was 44.49± 7.54, and WHR was 0.96± 0.06.
FVC∆ was correlated with WHR in male patients
(p � 0.018, r � 397). FEF25–75%∆ was statistically correlated
with FFM, TBW, and WHR in male patients (p< 0.05;
r � −0.344, r � −0.347, and r � 0.357, resp.; Table 3).
4. Discussion
(e present study demonstrated acute restrictive alterations
in respiratory functions in patients undergoing CA using
iso-osmolar contrast agents, and it remains altered at least 2
hours after CA. Furthermore, we revealed that respiratory
functions altered in obese and dehydrated or malnutrated
patients. (is observation might be a clue for a potential
mechanistic relationship between metabolic or volume
status and respiratory adverse effects of iso-osmolar contrast
agents used in high-risk patients.
CA remains the gold standard imaging modality to
diagnose coronary artery disease. In contrary to the wide
usage in clinical practice, CA has some limitations inherently
due to its invasive nature and the usage of iodine-based
contrast media. Historically, first-employed contrast media
agents were high-osmolar compared to blood osmolality and
had been accused for severe reactions including acute renal
failure, cardiovascular collapse, hemorrhage, atherosclerosis,
and death. It was well documented that high-osmolar
contrast agents caused acute plasma expansion and re-
leased vasoactive substances [7]. Second-generation nonionic
low-osmolar or iso-osmolar contrast media agents partly
overcame these problems and caused fewer contrast-induced
adverse events. It was shown that second-generation contrast
media agents cause also hemodynamic alterations tran-
siently in contrast to hyperosmolar agents. (e potential
mechanism of these acute alterations was suggested that
rising in cardiac output and alteration in blood cells
rheology is the major reason rather than pulmonary vas-
cular reactivity.
(e contrast agent can cause adverse respiratory reactions
such as overt bronchospasm, laryngeal oedema, cardiac failure
and loss of consciousness, and [8] pulmonary oedema. (ese
severe adverse reactions are rare, unpredictable, and poten-
tially fatal. (erefore, they must be recognized and treated
promptly to prevent permanent morbidity or death [9].
Pulmonary function tests are among the beneficial methods to
evaluate respiratory changes of patients. Lungs, chest wall, and
respiratory muscles play a significant role in the determination
of respiratory functions. If the results of these tests indicate
a restrictive pattern, it can be interpreted that the respiratory
disorders may have originated paranchim and so on; if these
results indicate an obstrictive pattern, the disorders may have
originated airway pathologies like broncoconstriction and so
on [10]. According to our results, angiography caused sig-
nificant reduction in FEV1, FVC, and FEF25–75% values, and
FEV1/FVC ratio was unchained. (ese reductions are in fa-
vour of asymptomatic restrictive pattern in pulmonary
functions. Ozhan et al. [11] reported in their study that di-
agnostic CA using iohexol, a hypo-osmolar contrast agent,
decreases ventilatory functions in a small but significant extent
in patients without any overt pulmonary disease. (ey have
suggested that contrast agent during CA increases the pul-
monary artery pressure possibly through several mechanisms:
a direct action on vascular smooth muscle, the release of
endogenous vasoactive mediators (such as endothelin,
Table 1: General characteristics of patients.
Patient characteristics Female (n � 25),n (%)
Male (n � 35),
n (%)
Smoking status
Smoker 9 (36) 14 (40)
<30 pack-years 6 (66.6) 6 (42)
≥30 pack-years 3 (33.4) 8 (58)
Nonsmoker 12 (48) 15 (42)
Ex-smoker 4 (16) 6 (17)
Systemic disorders
None 10 (40) 20 (57.1)
Hypertension 11 (44) 9 (25.7)
Diabetes mellitus 2 (8) 5 (14.3)
Others 2 (8) 1 (2.9)
Current medications
None 8 (32) 20 (57.1)
Βeta-blockers 6 (24) 1 (2.9)
Calcium-channel blockers 6 (24) 8 (22.9)
AT-II type receptor blockers 2 (8) 2 (5.7)
Others 3 (12) 4 (11.5)
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histamine, serotonin, and nitric oxide), neural reflexes, and
rheological properties of the red blood cells.
According to the literature, it was suggested that released
mediators may cause this condition. In the study of Simon
et al., it was demonstrated that plasma histamine, com-
plement haemolytic activity, and fibrin split products were
changed in patients undergoing radiographic contrast media
infusions [12]. Mast cells and basophiles are mainly re-
sponsible for mediator release, which may cause disorders.
Afterwards, the FcεR and the anaphylatoxin receptors (C5aR
and C3aR), which bind with IgE, C5a, and C3a, respectively,
the coactivation of the coagulation, and the kinin-kallikrein
systems participate in the inflammation cascade [13]. (ese
systems work together, and they can cause adverse effects.
Although these factors cause the main adverse effects,
studies demonstrated that these mediators’ changes and
clinical features hardly correlate [12]. (erefore, other
modulating factors may play significant roles in determining
whether a reaction will occur or not. For example, body
composition may also be another important factor for
evaluating the side effects; TBW can be a cheap, noninvasive
indicator to evaluate hydration; and also, respiratory
functions can rather be affected by fat mass, fat-free mass,
and so on[14, 15]; thus, we hypothesized that these factors
helps us to evaluate the respiratory performance. We in-
vestigated whether the total body composition can be a clue
to prevent the respiratory adverse effects, and our study
proved that, especially in male patients, FFM, WHR, and
TBW were statistically correlated with FEF25–75%∆, and
FVC∆ was correlated with WHR. Our findings can explain
the underlying mechanisms for the development of contrast
agents in particular conditions such as the reduced effective
intravascular volume or severe dehydration [16]. And also,
decreasing the incidence of renal failure induced by contrast
agent’s hydration can be explained by our findings that
higher TBW may decrease the adverse effects of contrast
agents.
Despite some investigations that evaluated the effects of
nonionic iso-osmolar contrast agents in respiratory func-
tions, our study was the first study that designed to find out
acute and short-term respiratory alterations using hypo-
osmolar contrast media agents during CA. Furthermore, we
suggested that body composition might be determinant of
respiratory alterations by altering pharmacokinetic prop-
erties of contrast media agents, and we measured body
composition parameters before CA and compared re-
spiratory parameters in a time-course manner.
Body composition might be a determinant of contrast
media agent-induced pulmonary impairment. Total body
water arises an easily available marker to get an insight into
volume status. It was well documented that dehydration is
the single preventable predictor of contrast-induced adverse
effects. Reduction of effective intravascular volume or severe
dehydration enables renal tubulointerstitial damage after
high-volume contrast exposure in high-risk patients [17].
Many randomized clinical trial data suggested that hydra-
tion prior to contrast exposure minimizes or prevents
contrast-induced renal damage and consequent systemic
inflammatory cascade. For this reason, it is logical that
estimation of high-risk patients beyond conventional risk
factors can decrease contrast-induced morbidity and mor-
tality. Furthermore, we showed that metabolic status in-
dicated by body fat mass can take a part in the pathogenesis
of contrast-induced side effects. Further experimental and
large-scale observational studies are needed to elucidate this
concept.
(e major limitations of our study are as follows:
(i) Partial oxygen saturation was not measured by blood gas
analysis to determine whether contrast-induced restrictive
pulmonary impairment caused subclinical hypoxemia.















(n � 25) 34.12± 6.91 6172.40± 823.53 40.68± 5.15 34.10± 11.52 47.56± 6.74 34.93± 4.99 0.85± 0.05
Male
(n � 35) 28.72± 6.12 7126.06± 1035.63 24.88± 8.23 21.80± 10.74 61.08± 9.06
∗ 44.49± 7.54∗ 0.96± 0.06∗
FEF25–75%∆ was statistically correlated with FFM, TBW, andWHR in men. FVC∆ was correlated with WHR. BMI: body mass index; BMR: body metabolism
rate; BFM: body fat mass; FFM: fat-free mass; TBW: total body water; WHR: waist-to-hip ratio. ∗p< 0.05.
Table 2: Alternations in respiratory functions during CA.
Pulmonary function test
Before CA At the end of CA 2 hours after CA
Female Male Female Male Female Male
FEV1% 103.40± 17.79 94.17± 18.83 94.96± 17.063# 84.45± 18.31## 95.20± 18.51# 84.25± 19.68##
FEV1 (L) 2.21± 0.42 2.89± 0.87 1.96± 0.48## 2.60± 0.68# 2.03± 0.48#: 2.65± 0.77#
FVC% 107.20± 19.03 96.57± 15.82 99.08± 20.56# 88.31± 17.96## 99.44± 19.69∗ 88.71± 17.82##
FVC (L) 2.73± 0.57 3.76± 0.97 2.45± 0.65## 3.39± 0.92## 2.53± 0.64# 3.52± 1.01#
FEF25–75% 83.92± 24.30 82.54± 24.26 73.24± 20.45# 72.11± 25.41## 74.48± 24.74# 71.85± 26.71##
FEF25–75% (L/s) 2.43± 0.54 2.81± 0.99 2.04± 0.63# 2.45± 0.88# 2.16± 0.67∗ 2.36± 0.91#
Pulmonary function tests were statically lower at the end of CA and 2 hours after CA. ∗p< 0.05; #p< 0.01; ##p≤ 0.001. FEV1: forced expiratory volume in 1 s;
FVC: forced vital capacity; FEF25–75%: forced expiratory flow between 25% and 75% of FVC.
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(ii) (e study patients were not followed beyond 2 hours.
(erefore, it cannot be concluded that acute alteration in
respiratory function had an impact on procedural morbidity
or mortality. For this reason, we cannot speculate about cost-
effectiveness of screening consecutive patients. (iii) (is
study indicated a significant association between acute re-
spiratory alteration and fat body mass. Nevertheless, it
cannot be a cause-effect relationship.
5. Conclusion
Our study demonstrated that diagnostic CA using iodixanol,
the iso-osmolar contrast media, causes significant reduction
in FEV1, FVC, and FEF25–75% in patients without any overt
pulmonary disease. (ese alternations were maintained at
each three values after 2 hours following the CA. Ventilatory
functions should be considered especially in patients whose
body composition or hydration is not within the desired
physiological range.
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